Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
ROCKVILLE, Md., May 10, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Gene Therapy and Gene Editing panel discussion at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 1:40 p.m. PT at the Encore Wynn in Las Vegas, NV. In addition, REGENXBIO senior management will be holding one-on-one meetings at the conference.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
